logo.jpg
ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO
April 15, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Dr. Loui Madakamutil, Noted Expert in Immunology and Autoimmune Diseases, as Chief Scientific Officer Marseille, France, April 15, 2021 – ImCheck Therapeutics today...
logo.jpg
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...
logo.jpg
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer
July 09, 2020 05:00 ET | ImCheck Therapeutics SAS
ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer First hire in the US will support growing global business development activities Marseille, France, July 9, 2020 – ImCheck...